#Taiwan #Frankfurt #Traditional Chinese Medicine #CPHI Frankfurt #Taiwan TCM

Taiwan's TCM Pavilion Shines at CPHI Frankfurt 2025

In a significant display of innovation and global collaboration, Taiwan's Traditional Chinese Medicine (TCM) Pavilion made its mark at the CPHI Frankfurt 2025 event held from October 28 to 30. Organized by the Department of Chinese Medicine and Pharmacy (DCMP) under the Ministry of Health and Welfare (MOHW), this pavilion attracted substantial international attention, reflecting Taiwan’s advancements in this ancient healthcare practice in a modern context.

The pavilion was a hub of activity during the event, drawing over 121 professional visitors, including industry leaders, researchers, and pharmaceutical distributors from multiple countries who expressed keen interest in exploring potential collaborations. It offered a unique platform where Taiwan’s TCM companies presented innovative solutions and engaged in discussions about distribution and manufacturing partnerships (OEM/ODM).

Among the notable moments was the pavilion's presentation on the CPHI Newsbeat, marking the inaugural occasion of a Taiwanese exhibitor being featured on this prominent international media platform. During this session, representatives outlined the development trajectory of Taiwan's TCM, followed by an engaging interview with Raman Sehgal, host of the Molecule to Market podcast, which amplified Taiwan's visibility on the world stage and generated significant media interest.

Key products highlighted included the NRICM101 and NRICM102 formulations, developed by the National Research Institute of Chinese Medicine (NRICM) and authorized by the MOHW. These formulas, substantiated by eleven peer-reviewed studies, showcase the capabilities of TCM in providing antiviral and anti-inflammatory effects. Notably, they have been shown to reduce ICU admissions and mortality rates for COVID-19 patients while protecting them against post-infectious complications like lung damage and brain fog.

Participating companies such as Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio illustrated Taiwan's comprehensive TCM ecosystem that encompasses clinical research, product innovation, GMP-certified manufacturing, and global OEM/ODM capabilities. The engaging nature of the exhibits fostered a collaborative spirit among attendees, inviting discussions on how to advance TCM's role in global healthcare.

Highlighting the positive responses, Mr. Mei-Shun Lo, Director General of the Taipei Representative Office in Germany, met with the pavilion team to discuss mutual interests. He, alongside Bertram Roth, Vice President of FrankfurtRheinMain GmbH, voiced strong support for evidence-based TCM initiatives from Taiwan, acknowledging its promising potential in the European market.

Dr. Yi-Chang Su, Director of DCMP and NRICM, emphasized, "The success of our participation at CPHI Frankfurt delineates Taiwan's commitment to integrating traditional medicine with modern healthcare dialogue worldwide." He expressed optimism towards future collaborations that would extend TCM innovations beyond borders, fostering enriched health outcomes for diverse populations globally.

The feedback received at this international trade exhibition indicates a fruitful pathway for Taiwan’s TCM to expand its influence, harnessing the latest scientific advancements and promoting traditional healing practices that are increasingly sought after in today’s healthcare landscape. As the world pivots towards holistic health solutions, Taiwan’s efforts stand out, aiming to bridge the gap between tradition and modernity in your pursuit of wellness.